Boston ScientificBoston Scientific (NYSE:BSX) shares were down before hours today on third-quarter results that were mixed compared to the consensus forecast.

The Marlborough, Massachusetts-based company posted profits of $419 million, or 28¢ per share, on sales of $2.9 billion for the three months ended Sept. 30, 2021, for a bottom-line gain from losses of $155 million this time last year on sales growth of 10.3%.

Adjusted to exclude one-time items, earnings per share were 41¢, 1¢ ahead of Wall Street, where analysts were looking for sales of $3 billion.

Each of Boston Scientific’s business segments experienced year-over-year revenue growth from 2020, with its cardiovascular business growing the most (19.4%). MedSurg increased by 11.2% and rhythm and neuro grew by 8.2%.

“We’ve seen this year that our strategy of category leadership, focus on high-growth markets and smart tuck-in M&A deals, combined with execution by our global team and an exciting pipeline, positions us well for the long term,” Boston Scientific Chairman & CEO Mike Mahoney said in a news release. “Despite some softness this quarter, including the ongoing impact of the COVID-19 pandemic, we’re confident that we will achieve our growth goals as the pandemic wanes.”

Boston Scientific said it now expects to log adjusted EPS of between $1.60 and $1.62 and projects its 2021 sales growth to range between 19% and 20%.

BSX shares were down -1.6% at $43.60 per share before the market opened today.